<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>

<channel>
	<title>Dr. Thomas Cowan: Holistic Family Medicine</title>
	<atom:link href="http://fourfoldhealing.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://fourfoldhealing.com</link>
	<description>Working With the Fourfold Laws of Nutrition, Therapeutics, Movement and Meditation in the Art of Medicine</description>
	<pubDate>Mon, 18 Aug 2008 01:50:31 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.1</generator>
	<language>en</language>
			<item>
		<title>Coenzyme Q10</title>
		<link>http://fourfoldhealing.com/2007/12/30/coenzyme-q10/</link>
		<comments>http://fourfoldhealing.com/2007/12/30/coenzyme-q10/#comments</comments>
		<pubDate>Mon, 31 Dec 2007 06:06:51 +0000</pubDate>
		<dc:creator>Sabine</dc:creator>
		
		<category><![CDATA[Dr. Cowan Talks On:]]></category>

		<guid isPermaLink="false">http://fourfoldhealing.com/?p=55</guid>
		<description><![CDATA[       One of the therapeutic “rules” I try to follow is to not use  isolated        “nutrients” in lieu of complex foods, herbs, and animal organ        preparations. The major exception I make to this rule [...]]]></description>
			<content:encoded><![CDATA[<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       One of the therapeutic “rules” I try to follow is to not use  isolated        “nutrients” in lieu of complex foods, herbs, and animal organ        preparations. The major exception I make to this rule is Coenzyme Q10        because, as you can see from the abstracts I have posted online, both the        research evidence and my personal experience has taught me that CoQ10 is a        valuable and safe medicine in a variety of situations.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">I        currently have four cancer patients whose cancers seem to be resolving,        that is either the tumors have shrunk or the tumor markers (e.g., </span>       <span style="font-size: 10pt; font-family: Arial">PSA</span><span style="font-size: 10pt; font-family: Arial">        or Thyroglobulin) have significantly decreased or gone down to normal. In        three of these cases, adding CoQ10 in therapeutic doses to the regimen        seemed to be the turning point. I have also seen good results with        patients with a variety of ailments of the heart and/or circulation who        have had positive responses to proper doses of CoQ10. And, as you can see        from the studies, CoQ10 has shown promise in the treatment of a variety of        neurological diseases including Parkinson&#8217;s disease, Multiple Sclerosis,        migraine headaches, and others. So what is this magic substance?</span></p>
<p>CoQ10, also known as Ubiquinone, so named because it is ubiquitous in our        cells, is a fat soluble (meaning found in fat, absorbed in fat, and        utilized in fat metabolism) &#8220;nutrient&#8221; that is a catalyst for the        production of energy from the mitochondria. This, of course, opens up        whole vistas of insights and questions. Is there a special reason for        these mitochondria that &#8220;produce&#8221; our energy? The best guess as to the        origin of mitochondria which are found in most cells (but not all) is that        they originally were free-living bacteria that parasitized our cells,        somehow got &#8220;stuck&#8221; in there and eventually made us their home. That is,        they embedded themselves in our individual (and other mammalian) cells so        that, presumably, we would provide them with food and shelter. In return,        they use our food and turn it into energy we need to carry out our lives.        CoQ10 seems to be the prime catalyst or stimulant to this mitochondrial        production of energy and probably its rate-limiting step. Therefore it        affects all health processes because one cannot heal, white blood cells        cannot migrate to the site of the infection or tumor, and circulation        cannot flow properly without adequate energy being generated by our        cells. This is the role of CoQ10.</p>
<p>CoQ10 is called an anti-oxidant in the literature, probably for this        reason: With a lack of energy, tissues are left unprotected and become        more subject to oxidative damage and, as one study shows, to the effects        of agricultural chemicals. Therefore, CoQ10 is needed in every        detoxification process in the same way that any process needs energy in        order to run. One of the continual tragedies of current medical practice        is the well known side effect of statin drugs. These drugs (Lipitor, Zocor,        etc.) deplete the body of its CoQ10 stores, probably because being a        toxin, it shifts the energy needs of the body in the direction of detoxing        the drug, leaving the patient exposed to fatigue, congestive heart        failure, and a host of neurological illnesses.</p>
<p>Also of note, the literature consistently suggests the use of high doses        of CoQ10 in the treatment of the various illnesses, at least 200 mg per        day in circulatory disorders and cancer and up to 2400 mg per day in        neurological illnesses. As followers of the <em>Nourishing Traditions</em>        dietary approach, we can probably do with less because the main dietary        sources of CoQ10 are the animal fats and liver which we value so much in        this regime. This is yet one more example of how the dietary wisdom of our        forefathers is being vindicated in modern medical studies.</p>
<p><font size="2">I have included        below a selection of papers, studies and trials that have been conducted        using CoQ10. Click on the link at Abstract to read the        full abstract at the National Center for Biotechnology        Information’s National Library of Medicine website,       <a href="http://www.ncbi.nlm.nih.gov/" target="_blank">www.ncbi.nlm.nih.gov</a>.</font></p>
<p><font size="2">Please note that this is for informational and        educational purposes only and is not intended to replace consultation with        a doctor.</font></p>
<p>*</p>
<p align="left">
<table border="0" height="26" width="600">
<tr>
<td style="border-style: solid; border-width: 1px" bgcolor="#d2d3d7"><strong>       Selected Papers                  </strong><font size="2">Abstracts link to NCBI&#8217;s National Library of Medicine        PubMed site</font></td>
</tr>
</table>
<p class="MsoNormal"><strong><em>       <span style="font-size: 10pt; font-family: Arial">Coenzyme Q10 affects        expression of genes involved in cell signalling, metabolism and transport        in human CaCo-2 cells.</span></em></strong></p>
<p><span style="font-size: 10pt; font-family: Arial"></span></p>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px">
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Groneberg DA, Kindermann B, Althammer M, Klapper M, Vormann J, Littarru        GP, Doring F.<br />
Biomedical Research Institute, Otto-Heubner-Centre, Charite School of        Medicine, Free University and Humboldt-University, D-13353 Berlin,        Germany.</span></p>
<p class="MsoNormal"><em><span style="font-size: 10pt; font-family: Arial">       Int J Biochem Cell Biol.</span></em><span style="font-size: 10pt; font-family: Arial">        2005 Jun;37(6):1208-18. Epub 2005 Jan 19.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15778085&amp;query_hl=1" target="_blank">       Abstract</a>:<br />
Coenzyme Q10 is an essential cofactor in the electron transport chain and        serves as an important antioxidant in both mitochondria and lipid        membranes. These findings indicate a prominent role of CoQ10 as a potent        gene regulator. The presently identified comprehensive list of genes        regulated by CoQ10 may be used for further studies to identify the        molecular mechanism of CoQ10 on gene expression.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">PMID</span><span style="font-size: 10pt; font-family: Arial">: 15778085<br />
</span></td>
</tr>
</table>
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px">
<p class="MsoNormal"><strong><em>       <span style="font-size: 10pt; font-family: Arial">Antioxidant treatment of        patients with Friedreich ataxia: four-year follow-up.</span></em></strong></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">Hart        PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C, Blamire AM,        Manners D, Styles P, Schapira AH, Cooper JM.<br />
University Department of Clinical Neurosciences, Royal Free and University        College Medical School, London, England.</span></p>
<p class="MsoNormal"><em><span style="font-size: 10pt; font-family: Arial">       Arch Neurol</span></em><span style="font-size: 10pt; font-family: Arial">.        2005 Apr;62(4):621-6.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15824263&amp;query_hl=3" target="_blank">       Abstract</a>:<br />
This study is intended to evaluate the long-term efficacy of a combined        antioxidant and mitochondrial enhancement therapy on the bioenergetics and        clinical course of FRDA. </span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Publication Types: Clinical Trial<br />
</span><span style="font-size: 10pt; font-family: Arial">PMID</span><span style="font-size: 10pt; font-family: Arial">: 15824263<br />
</span></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px">
<p class="MsoNormal"><strong><em>       <span style="font-size: 10pt; font-family: Arial">Role of mitochondria in        neuronal cell death induced by oxidative stress; neuroprotection by        Coenzyme Q10.</span></em></strong></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandey S.<br />
Department of Biochemistry and Chemistry, 277-1 Essex Hall, University of        Windsor, 401 Sunset Avenue, Windsor, ON, Canada N9B 3P4.</span></p>
<p class="MsoNormal"><em><span style="font-size: 10pt; font-family: Arial">       Neurobiol Dis.</span></em><span style="font-size: 10pt; font-family: Arial">        2005 Apr;18(3):618-27.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15755687&amp;query_hl=5" target="_blank">       Abstract</a>:<br />
Our study suggests that water-soluble Coenzyme Q10 acts by stabilizing the        mitochondrial membrane when neuronal cells are subjected to oxidative        stress. Therefore, Coenzyme Q10 has the potential to be used as a        therapeutic intervention for neurodegenerative diseases.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">PMID</span><span style="font-size: 10pt; font-family: Arial">: 15755687<br />
</span></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px">
<p class="MsoNormal"><strong><em>       <span style="font-size: 10pt; font-family: Arial">Efficacy of coenzyme Q10        in migraine prophylaxis: a randomized controlled trial.</span></em></strong></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel        L, Agosti RM, Schoenen J.<br />
Headache and Pain Unit, Neurology Department, University Hospital Zurich,        Frauenklinikstrasse 26, 8091 Zurich, Switzerland.</span></p>
<p class="MsoNormal"><em><span style="font-size: 10pt; font-family: Arial">       Neurology</span></em><span style="font-size: 10pt; font-family: Arial">.        2005 Feb 22;64(4):713-5</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15728298&amp;query_hl=7" target="_blank">       Abstract</a>:<br />
We compared CoQ10 (3 x 100 mg/day) and placebo in 42 migraine patients in        a double-blind, randomized, placebo-controlled trial. CoQ10 was superior        to placebo for attack-frequency, headache-days and days-with-nausea in the        third treatment month and well tolerated; CoQ10 is efficacious and well        tolerated.</span></p>
<p><span style="font-size: 10pt; font-family: Arial">PMID: 15728298<br />
</span></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px">
<p class="MsoNormal"><strong><em>       <span style="font-size: 10pt; font-family: Arial">Bovine cartilage,        coenzyme Q10, and wheat grass therapy for primary peritoneal cancer.</span></em></strong></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">Forgionne</span><span style="font-size: 10pt; font-family: Arial"> </span>       <span style="font-size: 10pt; font-family: Arial">GA.<br />
University</span><span style="font-size: 10pt; font-family: Arial"> of </span>       <span style="font-size: 10pt; font-family: Arial">Maryland</span><span style="font-size: 10pt; font-family: Arial">,        Baltimore County, Catonsville, MD 21250, USA.</span></p>
<p class="MsoNormal"><em><span style="font-size: 10pt; font-family: Arial">J        Altern Complement Med</span></em><span style="font-size: 10pt; font-family: Arial">.        2005 Feb;11(1):161-5.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15750376&amp;query_hl=9" target="_blank">       Abstract</a>:<br />
The accepted postsurgical first-line therapy for primary peritoneal cancer        has been a regime of chemotherapy. This paper reports the case of an        89-year-old female who refused chemotherapy but accepted a nutritional        alternative. Results after more than 4 years of the nutritional regime        have been encouraging with regards to objective and subjective measures.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Publication Types: Case Reports<br />
</span><span style="font-size: 10pt; font-family: Arial">PMID: 15750376<br />
</span></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px">
<p class="MsoNormal"><strong><em>       <span style="font-size: 10pt; font-family: Arial">Integrated treatment        approach improves cognitive function in demented and clinically depressed        patients.</span></em></strong></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Bragin V, Chemodanova M, Dzhafarova N, Bragin I, Czerniawski JL, Aliev G.<br />
Stress Relief and </span>       <span style="font-size: 10pt; font-family: Arial">Memory</span><span style="font-size: 10pt; font-family: Arial"> </span>       <span style="font-size: 10pt; font-family: Arial">Training</span><span style="font-size: 10pt; font-family: Arial"> </span>       <span style="font-size: 10pt; font-family: Arial">Center</span><span style="font-size: 10pt; font-family: Arial">,        Brooklyn, New York, USA.</span></p>
<p class="MsoNormal"><em><span style="font-size: 10pt; font-family: Arial">       Am J Alzheimers Dis Other Demen</span></em><span style="font-size: 10pt; font-family: Arial">.        2005 Jan-Feb;20(1):21-6.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15751450&amp;query_hl=11" target="_blank">       Abstract</a>:<br />
The purpose of this study was to evaluate the efficacy of an integrative        treatment approach on cognitive performance. </span></p>
<p><span style="font-size: 10pt; font-family: Arial">PMID: 15751450<br />
</span></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px">
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">[<strong><em>Coenzyme        Q10: biochemistry, pathophysiology of its deficiency and potential benefit        of an increased intake</em></strong>] </span><font size="1">       <span style="font-family: Arial">[Article in French]</span></font></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Malchair P, Van Overmeire L, Boland A, Salmon E, Pierard L, Seutin V.<br />
Service de Pharmacologie et CNCM, Universite de Liege.</span></p>
<p class="MsoNormal"><em><span style="font-size: 10pt; font-family: Arial">       Rev Med </span><span style="font-size: 10pt; font-family: Arial">Liege</span></em><span style="font-size: 10pt; font-family: Arial">. 2005 Jan;60(1):45-51.</span><span style="font-size: 10pt; font-family: Arial"> </span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15771317&amp;query_hl=13" target="_blank">       Abstract</a>:<br />
After a brief reminding of the synthesis and function of coenzyme Q10,        this article tries to summarise the current state of knowledge about the        consequences of its deficiency and about the potential benefits of an        increased intake of this coenzyme. We then describe the arguments in        favour of such an increase in cardiac diseases and in Parkinson&#8217;s disease.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">PMID</span><span style="font-size: 10pt; font-family: Arial">: 15771317<br />
</span></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px">
<p class="MsoNormal"><strong><em>       <span style="font-size: 10pt; font-family: Arial">Paraquat induces        oxidative stress and neuronal cell death; neuroprotection by water-soluble        Coenzyme Q10.</span></em></strong></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       McCarthy S, Somayajulu M, Sikorska M, Borowy-Borowski H, Pandey S.<br />
Chemistry and Biochemistry, </span>       <span style="font-size: 10pt; font-family: Arial">University</span><span style="font-size: 10pt; font-family: Arial"> of </span>       <span style="font-size: 10pt; font-family: Arial">Windsor</span><span style="font-size: 10pt; font-family: Arial">,        Windsor, Ontario, Canada.</span></p>
<p class="MsoNormal"><em><span style="font-size: 10pt; font-family: Arial">       Toxicol Appl Pharmacol</span></em><span style="font-size: 10pt; font-family: Arial">.        2004 Nov 15;201(1):21-31.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15519605&amp;query_hl=15" target="_blank">       Abstract</a>:<br />
Neuronal cell death induced by oxidative stress is correlated with        numerous neurodegenerative diseases, including Alzheimer&#8217;s disease (AD),        Parkinson&#8217;s disease (PD), and stroke. Pretreatment with CoQ10 was able to        inhibit ROS generation from isolated mitochondria as well as the collapse        of mitochondrial membrane potential. Our results indicate that        water-soluble CoQ10 can prevent oxidative stress and neuronal damage        induced by paraquat and therefore, can be used for the prevention and        therapy of neurodegenerative diseases caused by environmental toxins.</span></p>
<p><span style="font-size: 10pt; font-family: Arial">PMID: 15519605<br />
</span></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px">
<p class="MsoNormal"><strong><em>       <span style="font-size: 10pt; font-family: Arial">Pilot trial of high        dosages of coenzyme Q10 in patients with Parkinson&#8217;s disease</span></em></strong><span style="font-size: 10pt; font-family: Arial">.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Shults CW, Flint Beal M, Song D, Fontaine D.<br />
Department of Neurosciences, </span>       <span style="font-size: 10pt; font-family: Arial">University</span><span style="font-size: 10pt; font-family: Arial"> of </span>       <span style="font-size: 10pt; font-family: Arial">California</span><span style="font-size: 10pt; font-family: Arial">,        San Diego, La Jolla 92093-0662, USA.</span></p>
<p class="MsoNormal"><em><span style="font-size: 10pt; font-family: Arial">       Exp Neurol.</span></em><span style="font-size: 10pt; font-family: Arial">        2004 Aug;188(2):491-4.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15246848&amp;query_hl=17" target="_blank">       Abstract</a>:<br />
The safety and tolerability of high dosages of coenzyme Q10 were studied        in 17 patients with Parkinson&#8217;s disease (PD) in an open label study.  </span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Publication Types: Clinical Trial; Clinical Trial, Phase II<br />
</span><span style="font-size: 10pt; font-family: Arial">PMID</span><span style="font-size: 10pt; font-family: Arial">: 15246848<br />
</span></td>
</tr>
</table>
<p class="MsoNormal"><strong><em>       <span style="font-size: 10pt; font-family: Arial">Coenzyme Q10 in patients        with end-stage heart failure awaiting cardiac transplantation: a        randomized, placebo-controlled study.</span></em></strong></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP, Stamler A, Vered Y,        Vidne BA, Aravot D.<br />
Department of Cardiothoracic Surgery, Heart-Lung Transplant Unit, Rabin        Medical Center, Beilinson Campus, Potah Tikva, Israel.</span></p>
<p class="MsoNormal"><em><span style="font-size: 10pt; font-family: Arial">       Clin Cardiol.</span></em><span style="font-size: 10pt; font-family: Arial">        2004 May;27(5):295-9.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15188947&amp;query_hl=19" target="_blank">       Abstract</a>:<br />
The purpose of the present double-blind, placebo-controlled, randomized        study was to assess the effect of CoQ10 on patients with end-stage heart        failure and to determine if CoQ10 can improve the pharmacological bridge        to heart transplantation. The administration of CoQ10 to heart transplant        candidates led to a significant improvement in functional status, clinical        symptoms, and quality of life.</span></p>
<p class="MsoNormal"><span style="font-size: 10pt; font-family: Arial">       Publication Types: Clinical Trial, Randomized Controlled Trial<br />
</span><span style="font-size: 10pt; font-family: Arial">PMID</span><span style="font-size: 10pt; font-family: Arial">: 15188947</span></p>
]]></content:encoded>
			<wfw:commentRss>http://fourfoldhealing.com/2007/12/30/coenzyme-q10/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Boswellia</title>
		<link>http://fourfoldhealing.com/2007/12/30/boswellia/</link>
		<comments>http://fourfoldhealing.com/2007/12/30/boswellia/#comments</comments>
		<pubDate>Mon, 31 Dec 2007 06:05:26 +0000</pubDate>
		<dc:creator>Sabine</dc:creator>
		
		<category><![CDATA[Dr. Cowan Talks On:]]></category>

		<guid isPermaLink="false">http://fourfoldhealing.com/?p=54</guid>
		<description><![CDATA[There are many plants in history that have been revered for their medicinal value, others whose renown has been due to their religious or spiritual value. Boswellia serrata is one of the rare plants that “lives” in both of these worlds.
Boswellia, also known as Frankincense, is a large shrub that particularly likes the hot, dry [...]]]></description>
			<content:encoded><![CDATA[<p>There are many plants in history that have been revered for their medicinal value, others whose renown has been due to their religious or spiritual value. Boswellia serrata is one of the rare plants that “lives” in both of these worlds.</p>
<p>Boswellia, also known as Frankincense, is a large shrub that particularly likes the hot, dry climates of the Near Eastern lands. It is primarily associated with ancient Persia, in the place we now call Iran, but it grows in many other places in the world. Boswellia’s religious significance is best represented by its use as one of the gifts of the Magi to the Christ child. It is also the incense used in the Roman Catholic Mass and other religious events as a way to call people to worship, to focus their attention on the spiritual matters at hand. Its primary medical use has been as a medicine to “warm the joints”, to relieve stiffness, and to, in general, reduce inflammation. Our question is, what do these phenomena have in common, how do they interrelate?</p>
<p>In Anthroposophical literature, the “Christ event” was associated with the birth of the ego in the world of humans. In more general terms, I would interpret this time as a turning point, maybe represented by that event, when humans became able to be more self-conscious than they had previously. People began to identify less with a tribe or group and more as individuals standing apart from others. The history of the past two thousand years reflects this individuation as the theme of humanity as we struggle to know ourselves and define ourselves more and more as individuals, apart even from our immediate families. In other words, unlike in former times, we no longer have to have the same profession or even speak the same language as our tribe or even our families. As those who have read The Fourfold Path to Healing know, this ego is the seat of our warmth body, the element in us that regulates and guards or protects our ability to generate warmth.</p>
<p>In medicine, the warmth body is considered the captain of the ship in the sense that an inflammation without a fever (hence the increased involvement of the warmth body) can easily become the setting for the inflammation becoming the type of chronic condition that is at the root of so many of our chronic ailments. Asthma is a chronic inflammation in the lungs, colitis in the intestines, eczema of the skin, etc. Even coronary artery disease is now considered to arise from chronic inflammation in the coronary arteries. In all these cases, increasing the warmth principle will help guide the inflammation to its conclusion, much as the fever guides the inflammation to its ultimate healing. For all these conditions, Boswellia as a medicine has been shown in the medical literature to provide relief. In essence, Boswellia guides us in this process of individuation, or self-awareness, that is so intimately wrapped up with the task of humanity in our current age. It does this by increasing our warmth, exactly that part of us that makes us human. It warms our hearts (the organ of the warmth body), increases our circulation, and works towards bringing to a healthy conclusion the unresolved aspects (i.e. inflammations) in our lives.</p>
<p>Because I use boswellia in my practice, I share with you below several research papers and studies on this therapeutic treatment.</p>
<p>I have included below a selection of papers, studies and trials that have been conducted using boswellia. Click on the link at Abstract to read the full abstract at the National Center for Biotechnology Information’s National Library of Medicine website, <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a>.</p>
<p>Please note that this is for informational and educational purposes only and is not intended to replace consultation with a doctor.</p>
<p align="center"><strong>Selected Papers Abstracts link to NCBI’s National Library of Medicine PubMed site</strong></p>
<p><em><strong>Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascular endothelial cells.</strong></em></p>
<p>Roy S, Khanna S, Shah H, Rink C, Phillips C, Preuss H, Subbaraju GV, Trimurtulu G, Krishnaraju AV, Bagchi M, Bagchi D, Sen CK.<br />
Laboratory of Molecular Medicine, Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio 43210, USA.</p>
<p>DNA Cell Biol. 2005 Apr;24(4):244-55.<br />
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15539433">Abstract</a>:<br />
Inflammatory disorders represent a substantial health problem. Medicinal plants belonging to the Burseraceae family, including Boswellia, are especially known for their anti-inflammatory properties. Realtime PCR studies showed that while TNF alpha potently induced VCAM-1 gene expression, BE completely prevented it. This result confirmed our microarray findings and built a compelling case for the anti-inflammatory property of BE. In an in vivo model of carrageenan-induced rat paw inflammation, we observed a significant antiinflammatory property of BE consistent with our in vitro findings. These findings warrant further research aimed at identifying the signaling mechanisms by which BE exerts its anti-inflammatory effects.</p>
<p>PMID: 15812241</p>
<p><em><strong>Effects of Boswellia serrata in mouse models of chemically induced colitis</strong></em>.<br />
Kiela PR, Midura AJ, Kuscuoglu N, Jolad SD, Solyom AM, Besselsen DG, Timmermann BN, Ghishan FK.<br />
Dept. of Pediatrics, Children’s Research Center, Univ. of Arizona, 1501 N. Campbell Ave., Tucson, AZ 85724, USA. Am J Physiol Gastrointest Liver Physiol. 2005 Apr;288(4):G798-808. Epub 2004 Nov 11.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=pubmed&#038;dopt=Abstract&#038;list_uids=15539433">Abstract</a>:<br />
The goal of this study was to evaluate the effectiveness of boswellia extracts in controlled settings of dextran sulfate- or trinitrobenzene sulfonic acid-induced colitis in mice.</p>
<p>PMID: 15539433</p>
<p><em><strong>Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells.<br />
</strong></em>Xia L, Chen D, Han R, Fang Q, Waxman S, Jing Y. Division of Hematology/Oncology, Department of Medicine, Box 1178, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6547.<br />
Mol Cancer Ther. 2005 Mar;4(3):381-8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15767547"></a></p>
<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15767547">Abstract</a>:<br />
The mechanism of the cytotoxic effect of boswellic acid acetate, a 1:1 mixture of alpha-boswellic acid acetate and beta-boswellic acid acetate, isolated from Boswellia carterri Birdw on myeloid leukemia cells was investigated in six human myeloid leukemia cell lines (NB4, SKNO-1, K562, U937, ML-1, and HL-60 cells). Data taken together suggest that boswellic acid acetate induces myeloid leukemia cell apoptosis through activation of caspase-8 by induced expression of DR4 and DR5.PMID: 15767547</p>
<p><em><strong>Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee–a randomized double blind placebo controlled trial.</strong></em><br />
Kimmatkar N, Thawani V, Hingorani L, Khiyani R.<br />
MS Orthopedics, Indira Gandhi Medical College, Nagpur, India.  Phytomedicine. 2003 Jan;10(1):3-7.<br />
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12622457&amp;dopt=Abstract">Abstract</a>:<br />
A randomized double blind placebo controlled crossover study was conducted to assess the efficacy, safety and tolerability of Boswellia serrata Extract (BSE) in 30 patients of osteoarthritis of knee, 15 each receiving active drug or placebo for eight weeks. BSE is recommended in the patients of osteoarthritis of the knee with possible therapeutic use in other arthritis.</p>
<p>Publication Types: Clinical Trial, Randomized Controlled Trial   PMID: 12622457</p>
<p><em><strong>Therapy of active Crohn disease with Boswellia serrata extract H 15 [Article in German]</strong></em><br />
Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R.<br />
Colitis-Crohn-Ambulanz, I. Medizinische Klinik, Klinikum Mannheim der Universitat Heidelberg.  Z Gastroenterol. 2001 Jan;39(1):11-7.<br />
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11215357&amp;dopt=Abstract">Abstract</a>:<br />
The purpose of this clinical trial was to compare efficacy and safety of the Boswellia serrata extract H15 with mesalazine for the treatment of active Crohn’s disease. CONCLUSIONS: The study confirms that therapy with H15 is not inferior to mesalazine, which can be interpreted as evidence for the efficacy of H15 according to the state of art in the treatment of active Crohn’s disease with Boswellia serrata extract, since the efficacy of mesalazine for this indication has been approved by the health authorities. Considering both safety and efficacy of Boswellia serrata extract H15 it appears to be superior over mesalazine in terms of a benefit-risk-evaluation.</p>
<p>Publication Types: Clinical Trial, Randomized Controlled Trial  PMID: 11215357</p>
<p><em><strong>Effects of gum resin of Boswellia serrata in patients with chronic colitis.</strong></em><br />
Gupta I, Parihar A, Malhotra P, Gupta S, Ludtke R, Safayhi H, Ammon HP.<br />
Department of Medicine, Medical College Jammu, J&amp;K, India.</p>
<p>Planta Med. 2001 Jul;67(5):391-5.<br />
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11488449&amp;dopt=Abstract">Abstract</a>:<br />
Patients studied here suffered from chronic colitis characterized by vague lower abdominal pain, bleeding per rectum with diarrhoea and palpable tender descending and sigmoid colon. This study shows that a gum resin preparation from Boswellia serrata could be effective in the treatment of chronic colitis with minimal side effects.</p>
<p>Publication Types: Clinical Trial, Randomized Controlled Trial  PMID: 11488449</p>
<p><em><strong>Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study.</strong></em><br />
Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, Ammon HP.<br />
Pharmakologie fur Naturwissenschaftler, Pharmazeutisches Institut der Universitat Tubingen, Auf der Morgenstelle 8, D-72076 Tubingen, Germany.  Eur J Med Res. 1998 Nov 17;3(11):511-4.</p>
<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9810030&amp;dopt=Abstract">Abstract</a>:<br />
In a double-blind, placebo-controlled study forty patients, the data show a definite role of gum resin of Boswellia serrata in the treatment of bronchial asthma.</p>
<p>Publication Types: Clinical Trial, Randomized Controlled Trial  PMID: 9810030</p>
<p><em><strong>Is H15 (resin extract of Boswellia serrata, “incense”) a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study [Article in German]</strong></em><br />
Sander O, Herborn G, Rau R.<br />
Rheumatologische Klinik, Evangelisches Fachkrankenhaus Ratingen.  Z Rheumatol. 1998 Feb;57(1):11-6<br />
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9566100&amp;dopt=Abstract">Abstract</a>:<br />
BACKGROUND: Leukotrienes and prostaglandines are important mediators of inflammation. Resinous extracts of Boswellia serrata (H15, indish incense), known from traditional ayurvedic medicine, decrease leukotriene synthesis in vitro. Case reports suggest a clinical role for that drug. Controlled studies including a greater patient population are necessary to confirm or reject our results.</p>
<p>Publication Types: Clinical Trial , Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial  PMID: 9566100</p>
<p><em><strong>Effects of Boswellia serrata gum resin in patients with ulcerative colitis.</strong></em><br />
Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, Ammon HP.<br />
Department of Medicine, Govt. Medical College, Jammu, J&amp;K, India.  Eur J Med Res. 1997 Jan;2(1):37-43.<br />
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9049593&amp;dopt=Abstract">Abstract</a>:<br />
In patients suffering from ulcerative colitis grade II and III the effect of Boswellia serrata gum resin preparation (350 mg thrice daily for 6 weeks) on stool properties, histolopathology and scan microscopy of rectal biopsies, blood parameters including Hb, serum iron, calcium, phosphorus, proteins, total leukocytes and eosinophils was studied. All parameters tested improved after treatment with Boswellia serrata gum resin, the results being similar compared to controls: 82% out of treated patients went into remission; in case of sulfasalazine remission rate was 75%.</p>
<p>Publication Types: Clinical Trial, Controlled Clinical Trial  PMID: 9049593</p>
<p><em><strong>Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study.</strong></em><br />
Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B.<br />
Bryamjee Jeejeebhoy Medical College, University of Poona, Pune, India.  J Ethnopharmacol. 1991 May-Jun;33(1-2):91-5.<br />
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1943180&amp;dopt=Abstract">Abstract</a>:<br />
The clinical efficacy of a herbomineral formulation containing roots of Withania somnifera, the stem of Boswellia serrata, rhizomes of Curcuma longa and a zinc complex (Articulin-F), was evaluated in a randomized, double-blind, placebo controlled, cross-over study in patients with osteoarthritis.</p>
<p>PMID: 1943180</p>
]]></content:encoded>
			<wfw:commentRss>http://fourfoldhealing.com/2007/12/30/boswellia/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Bee Venom</title>
		<link>http://fourfoldhealing.com/2007/12/30/bee-venom/</link>
		<comments>http://fourfoldhealing.com/2007/12/30/bee-venom/#comments</comments>
		<pubDate>Mon, 31 Dec 2007 06:04:06 +0000</pubDate>
		<dc:creator>Sabine</dc:creator>
		
		<category><![CDATA[Dr. Cowan Talks On:]]></category>

		<guid isPermaLink="false">http://fourfoldhealing.com/?p=53</guid>
		<description><![CDATA[Bee venom therapy is a specific treatment that I use for        patients with arthritis. Although use of bee stings to treat        osteoarthritis may raise eyebrows, it is in fact a therapy that was widely        [...]]]></description>
			<content:encoded><![CDATA[<p>Bee venom therapy is a specific treatment that I use for        patients with arthritis. Although use of bee stings to treat        osteoarthritis may raise eyebrows, it is in fact a therapy that was widely        used in folk medicine. Peasants throughout the world have used the        practice of placing honey bees on their sore joints and muscles to treat        their arthritis and pain.</p>
<p>We do not know the exact reasons why bee venom therapy        works, or which specific components of bee venom have a healing effect.        Consider, however, the fact that conditions like osteoarthritis, bursitis        and tendonitis are due to a gradual process of sclerosis or        mineralization. The body attempts to bring balance in these situations by        creating an inflammation, but in many cases the body’s attempt to heal        through inflammation is too weak.</p>
<p>Stinging the sore joint with a honey bee dramatically        increases inflammation and brings more blood to the area. Bee venom has a        component that relieves pain, by bringing bringing warmth to the affected        area. The warmth and inflammation from the bee sting also increases the        body’s ability to dissolve excessive mineralizations. As a potent local        stimulator of inflammation, bee venom thus fulfills exactly the healing        requirements for osteoarthritis. It increases the heat or warmth in the        joint, and it increases the ability of the body to dissolve the excessive        mineral deposits that are the hallmark of arthritis.</p>
<p>Because I use bee venom therapy in my practice, I share        with you below several research papers and studies on this therapeutic        treatment.</p>
<p>I have included        below a selection of papers, studies and trials that have been conducted        using bee venom therapy. Click on the link at Abstract to read the        full abstract at the National Center for Biotechnology        Information’s National Library of Medicine website,       <a href="http://www.ncbi.nlm.nih.gov/" target="_blank">www.ncbi.nlm.nih.gov</a>.</p>
<p>Please note that this is for informational and        educational purposes only and is not intended to replace consultation with        a doctor.</p>
<p align="left">&nbsp;</p>
<p><strong>       Selected Papers                  </strong><font size="2">Abstracts link to NCBI&#8217;s National Library of Medicine        PubMed site</font></p>
<p align="left"> <em><strong><font size="2">       Antiarthritic effect of bee venom: inhibition of inflammation mediator        generation by suppression of NF-kappaB through interaction with the p50        subunit. </font></strong></em><font size="2">Park HJ, Lee SH, Son DJ, Oh KW, Kim KH, Song HS, Kim GJ,        Oh GT, Yoon do Y, Hong JT.<br />
College of Pharmacy, Chungbuk National University, 48 Gaesin-dong,        Heungduk-gu, Cheongju, Chungbuk 361-763, South Korea. </font><font size="2"><em>Arthritis Rheum</em>. 2004 Nov;50(11):3504-15.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15529353" target="_blank">       Abstract</a><br />
To investigate the molecular mechanisms of the anti-arthritic effects of        bee venom and melittin, a major component of bee venom, in patients with        rheumatoid arthritis.</font></p>
<p><font size="2">PMID: 15529353</font></p>
<p align="left">
<em><strong>Anti-inflammatory effect of bee venom on type II        collagen-induced arthritis.</strong></em> </font><font size="2">Lee JD, Kim SY, Kim TW, Lee SH, Yang HI, Lee DI, Lee YH.<br />
Research Group of Pain and Neuroscience in Vision 2000 Project East-West        Medical Research Institute, Kyung Hee University, Seoul, Korea.</font><font size="2"><em>Am J Chin Med</em>. 2004;32(3):361-7.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15344419" target="_blank">       Abstract</a><br />
This study was designed to evaluate the anti-inflammatory and        anti-cytokine effect of bee venom on a murine type-II collagen-induced        arthritis (CIA) model. </font><font size="2">PMID: 15344419</font><br />
<em><strong><font size="2">Inhibition of COX-2 activity and proinflammatory        cytokines (TNF-alpha and IL-1beta) production by water-soluble        sub-fractionated parts from bee (Apis mellifera) venom. </font></strong></em><font size="2">Nam KW, Je KH, Lee JH, Han HJ, Lee HJ, Kang SK, Mar W.<br />
Natural Products Research Institute, Seoul National University, Seoul        110-460, Korea. </font><font size="2"><em>Arch Pharm Res</em>. 2003 May;26(5):383-8.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12785734" target="_blank">       Abstract</a><br />
A study of the anti-inflammatory activity of the n-hexane, ethyl acetate,        and aqueous partitions from bee venom (Apis mellifera).</font><font size="2">PMID: 12785734</font><br />
<em><strong><font size="2">The effect of whole bee venom on arthritis. </font>       </strong></em><font size="2">Kang SS, Pak SC, Choi SH.<br />
College of Veterinary Medicine and Research Institute of Veterinary        Medicine, Chungbuk National University, Cheongju, Korea. </font><font size="2"><em>Am J Chin Med.</em> 2002;30(1):73-80. </font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12067099" target="_blank">       Abstract</a><br />
This study was performed to assess the clinicotherapeutic effect of whole        venom of honeybee (Apis mellifera) in adjuvant-induced arthritic rat.</font><font size="2">PMID: 12067099</font><br />
<em><strong><font size="2">The analgesic efficacy of bee venom acupuncture for        knee osteoarthritis: a comparative study with needle acupuncture. </font>       </strong></em><font size="2">Kwon YB, Kim JH, Yoon JH, Lee JD, Han HJ, Mar WC, Beitz        AJ, Lee JH.<br />
Department of Veterinary Physiology, College of Veterinary Medicine and        School of Agricultural Biotechnology, Seoul National University, Suwon,        Korea. </font><font size="2"><em>Am J Chin Med.</em> 2001;29(2):187-99.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11527062" target="_blank">       Abstract</a><br />
A study to determine whether bee venom (BV) administered directly into an        acupoint was a clinically effective and safe method for relieving the pain        of patients with knee osteoarthritis (OA) as compared to traditional        needle acupuncture.</font><font size="2">Publication Types: Clinical Trial, Randomized Controlled        Trial </font></p>
<p><font size="2">PMID: 11527062</font></p>
]]></content:encoded>
			<wfw:commentRss>http://fourfoldhealing.com/2007/12/30/bee-venom/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Turmeric</title>
		<link>http://fourfoldhealing.com/2007/12/30/turmeric/</link>
		<comments>http://fourfoldhealing.com/2007/12/30/turmeric/#comments</comments>
		<pubDate>Mon, 31 Dec 2007 06:02:58 +0000</pubDate>
		<dc:creator>Sabine</dc:creator>
		
		<category><![CDATA[Dr. Cowan Talks On:]]></category>

		<guid isPermaLink="false">http://fourfoldhealing.com/?p=52</guid>
		<description><![CDATA[Imagine if the pharmaceutical industry came up with a        new &#8220;drug&#8221; that helped your body clear toxins from the liver by increasing        the bile flow; protected your DNA against mutations from such things as        [...]]]></description>
			<content:encoded><![CDATA[<p>Imagine if the pharmaceutical industry came up with a        new &#8220;drug&#8221; that helped your body clear toxins from the liver by increasing        the bile flow; protected your DNA against mutations from such things as        toxic chemicals and ionizing radiation; chelated (removed) heavy metals        such as lead and aluminum from your body; stabilized the telomeres, the        proteins that control aging; was shown to be an effective preventative        agent against Alzheimer&#8217;s disease; was completely non-toxic as evidenced        by hundreds if not thousands of years of use, and cost less than $10 per        month to use. Imagine the gratitude people would feel from having access        to such a wonderful medicine. </p>
<p>As the following research articles show, there is just        such a medicine. And rather than being discovered by the drug industry, it        has been one of the main medicines and culinary items used throughout the        world for literally thousands of years. The amazing medicine is turmeric,        otherwise known as the coloring agent in Indian curry powder. I use        turmeric probably more than any other medicine in my practice. In fact I        take a teaspoon or a few capsules per day myself. I am happy to share with        you some of what I have learned about this amazing plant.</p>
<p>You might also like to read Koohan Paik&#8217;s piece about        Turmeric (with a couple of recipes) in the quarterly journal, <em>slow: the        international herald of taste</em> (<a href="http://www.slowfood.it/img_sito/riviste/slow/EN/21/en_curcuma.html" target="_blank">issue        n° 21, april - june 2000</a>) in which he says: “…all plants have some        relationship with the human body, and&#8230;in the shaman’s world, no plant is        useless. But if there was any single piece of knowledge that Mr. Ohai made        sure each student came away with, it was the importance of turmeric, the        basis of all Hawaiian healing.”</p>
<p>I have included        below a selection of papers, studies and trials that have been conducted        using curcumin, the pigment from turmeric. Click on the link at Abstract to read the        full abstract at the National Center for Biotechnology        Information’s National Library of Medicine website,       <a href="http://www.ncbi.nlm.nih.gov/" target="_blank">www.ncbi.nlm.nih.gov</a>.</p>
<p>I have had numerous requests from patients who are        undergoing treatment for cancer, particularly Iscador therapy, who would        like to talk with other patients about their experiences. We want to act        as a conduit to put people in touch with one another so they can get more        information and share stories. The focus of this       <a href="http://www.fourfoldhealing.com/cancer-discussion">cancer discussion forum</a> is on        patients and their experiences. It will be wholly the effort of those who        have an interest. I will not be involved in any way except as the initial        facilitator for putting people together through a confidential email        exchange. <a href="http://www.fourfoldhealing.com/cancer-discussion">Click here for more        information</a>&#8230;</p>
<p><em><strong>Please note that this is intended for informational and        educational purposes only and is not intended to replace consultation with        a doctor.</strong></em></p>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px" bgcolor="#d2d3d7"><strong>       Selected Papers                  </strong><font size="2">Abstracts link to NCBI&#8217;s National Library of Medicine        PubMed site</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">       Astrocyte production of the chemokine macrophage inflammatory protein-2 is        inhibited by the spice principle curcumin at the level of gene        transcription.</font></strong></em><font size="2"> </font><font size="2">Tomita M, Holman BJ, Santoro CP, Santoro TJ. </font><font size="2">Department of Medicine, University of North Dakota School of Medicine &amp;        Health Sciences, 501 North Columbia Road, Grand Forks, ND 58201, USA.       <a href="mailto:mtomita@medicine.nodak.edu">mtomita@medicine.nodak.edu</a>.</font></p>
<p><font size="2"></font></p>
<p><font size="2"><em>J Neuroinflammation</em>. 2005 Feb 25;2(1): 8.</font><font size="2"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15733321" target="_blank">       Abstract</a></font></p>
<p><font size="2">Curcumin&#8217;s immunomodulating and antioxidant activities suggest that it        might be a useful adjunct in the treatment of neurodegenerative illnesses        characterized by inflammation. Relatively unexplored, but relevant to its        potential therapeutic efficacy in neuroinflammatory syndromes is the        effect of curcumin on chemokine production. Results offer further support        for its potential use in the treatment of inflammatory conditions of the        CNS.</font><font size="2">PMID: 15733321</font></td>
</tr>
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">       Antiangiogenic agents: studies on fumagillin and curcumin analogs.</font></strong></em><font size="2"> </font><font size="2">Furness MS, Robinson TP, Ehlers T, Hubbard RB 4th, Arbiser JL, Goldsmith        DJ, Bowen JP. </font><font size="2">Department of Chemistry and Biochemistry, 435 New Science Building, PO Box        26170, University of North Carolina at Greensboro, Greensboro, NC 27402,        USA.</font></p>
<p><font size="2"></font></p>
<p><font size="2"><em>Curr Pharm Des.</em> 2005;11(3): 357-73.</font><font size="2"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15723631" target="_blank">       Abstract</a></font></p>
<p><font size="2">This paper describes efforts to design and prepare fumagillin and curcumin        analogs and evaluate their corresponding antiangiogenic activities.</font><font size="2">PMID: 15723631</font></td>
</tr>
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">       Curcumin induces glutathione biosynthesis and inhibits NF-kappa B        activation and interleukin-8 release in alveolar epithelial cells:        mechanism of free radical scavenging activity.</font></strong></em><font size="2"> </font><font size="2">Biswas SK, McClure D, Jimenez LA, Megson IL, Rahman I. </font><font size="2">Centre for Cardiovascular Sciences, School of Biomedical and Clinical        Laboratory Sciences, University of Edinburgh, Medical School, Edinburgh,        UK.</font></p>
<p><font size="2"></font></p>
<p><font size="2"><em>Antioxid Redox Signal</em>. 2005 Jan-Feb;7(1-2):32-41.</font><font size="2"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15650394" target="_blank">       Abstract</a></font></p>
<p><font size="2">This study suggests that curcumin has multiple properties: as an oxygen        radical scavenger, antioxidant through modulation of glutathione levels,        and anti-inflammatory agent through inhibition of IL-8 release in lung        cells.</font><font size="2">PMID: 15650394</font></td>
</tr>
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">       Curcumin blocks homocysteine-induced endothelial dysfunction in porcine        coronary arteries.</font></strong></em><font size="2"> </font><font size="2">Ramaswami G, Chai H, Yao Q, Lin PH, Lumsden AB, Chen C. </font><font size="2">Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey        Department of Surgery,</font></p>
<p><font size="2">Baylor College of Medicine, Houston, TX 77030, USA.</font></p>
<p><font size="2"></font></p>
<p><font size="2"><em>J Vasc Surg.</em> 2004 Dec;40(6):1216-22.</font><font size="2"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15622377" target="_blank">       Abstract</a></font></p>
<p><font size="2">The objective of this study was to determine the effect of curcumin on        homocysteine-induced endothelial dysfunction in a porcine coronary artery        model. Results suggest a therapeutic role for dietary curcumin in patients        with homocysteinemia, thereby reducing cardiovascular morbidity and        mortality. Thus curcumin could be used in patients with        hyperhomocysteinemia, and to prevent cardiovascular diseases.</font><font size="2">PMID: 15622377</font></td>
</tr>
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">In        vitro and in vivo anti-tumoral effect of curcumin against melanoma cells.</font></strong></em><font size="2"> </font><font size="2">Odot J, Albert P, Carlier A, Tarpin M, Devy J, Madoulet C. </font><font size="2">Laboratoire de Biologie Cellulaire et Moleculaire, EA 3306 U.F.R Sciences,        Reims, France.</font></p>
<p><font size="2"></font></p>
<p><font size="2"><em>Int J Cancer. </em>2004 Sep 1;111(3):381-7.</font><font size="2"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15221965" target="_blank">       Abstract</a></font></p>
<p><font size="2">In the current study, curcumin may provide a valuable tool for the        development of a therapeutic combination against the melanoma.</font><font size="2">PMID: 15221965</font></td>
</tr>
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">       <em><strong>Curcumin inhibits telomerase activity through human telomerase        reverse transcritpase in MCF-7 breast cancer cell line.</strong></em></font>       <font size="2">Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, Melnick        SJ. </font><font size="2">Department of Pathology, Miami Children&#8217;s Hospital, 3100 SW 62nd Avenue,        FL 33155, USA.</font><font size="2"><em>Cancer Lett. </em>2002 Oct 8;184(1):1-6.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12104041" target="_blank">Abstract</a></font></p>
<p><font size="2">The inhibitory effect of curcumin, the yellow-colored pigment from        turmeric, on telomerase activity was analyzed in human mammary epithelial        and breast cancer cells.</font><font size="2">PMID: 12104041</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Through metal binding, curcumin protects against        lead- and cadmium-induced lipid peroxidation in rat brain homogenates and        against lead-induced tissue damage in rat brain.</font></strong></em><font size="2">Daniel S, Limson JL, Dairam A, Watkins GM, Daya S </font><font size="2">Department of Biochemistry, Microbiology and Biotechnology and Faculty of        Pharmacy, Rhodes University, P.O. Box 94, Grahamstown, South Africa</font><font size="2"><em>J Inorg Biochem</em>. 2004 Feb;98(2):266-75.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14729307" target="_blank">       Abstract</a></font></p>
<p><font size="2">This study examines the ability of curcumin (tumeric) to protect against        lead-induced damage to hippocampal cells of male Wistar rats, as well as        lipid peroxidation induced by lead and cadmium in rat brain homogenate.</font></p>
<p><font size="2">PMID: 14729307</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Protective effect of curcumin against lead        neurotoxicity in rats</strong></em>.</font><font size="2">Shukla PK, Khanna        VK, Khan MY, Srimal RC. </font><font size="2">Industrial Toxicology Research Centre, PO Box 80, MG Marg, Lucknow 226001,        India. </font><font size="2"><em>Hum Exp Toxicol</em>. 2003 Dec;22(12):653-8.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14992327" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study to investigate the protective effect of curcumin against        lead-induced neurotoxicity in rats. </font><font size="2">PMID: 14992327 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Chemotherapeutic potential of curcumin for colorectal        cancer.</strong></em></font><font size="2">Chauhan DP. </font><font size="2">Division of Gastroenterology, Department of Medicine, The University of        California, San Diego, CA 92093-0688, USA</font><font size="2"><em>Curr Pharm Des</em>. 2002;8(19):1695-706.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12171541" target="_blank">       Abstract</a></font></p>
<p><font size="2">Epidemiological data also suggest that curcumin may be responsible for the        lower rate of colorectal cancer in some countries and is a naturally        occurring powerful anti-inflammatory medicine.</font><font size="2">Publication Types: Review, Tutorial</font></p>
<p><font size="2">PMID: 12171541 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>The inhibition of the estrogenic effects of        pesticides and environmental chemicals by curcumin and isoflavonoids.</strong></em></font>       <font size="2">Verma SP, Goldin BR, Lin PS. </font><font size="2">Department of Family Medicine and Community Health, Tufts University        School of Medicine, Boston, MA 02111 USA. </font><font size="2"><em>Environ Health Perspect.</em> 1998 Dec;106(12):807-12.       </font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9831541" target="_blank">       Abstract</a></font></p>
<p><font size="2">A study looking at the development of dietary strategies to prevent the        stimulated growth of breast tumors by environmental estrogens.</font><font size="2">PMID: 9831541</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Curcumin inhibits interleukin 8 production and        enhances interleukin 8 receptor expression on the cell surface:impact on        human pancreatic carcinoma cell growth by autocrine regulation.</strong></em></font>       <font size="2">Hidaka H, Ishiko T, Furuhashi T, Kamohara H, Suzuki S,        Miyazaki M, Ikeda O, Mita S, Setoguchi T, Ogawa M. </font><font size="2">Department of Surgery I, Miyazaki Medical College, Japan.</font><font size="2"><em>Cancer.</em> 2002 Sep 15;95(6):1206-14. </font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12216086" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study of the effect of curcumin on human carcinoma cell lines to determine        whether constitutive interleukin-8 (IL-8) production of tumor cells was        correlated with nuclear factor kappaB (NF-kappaB) activation and cell        growth activity.</font><font size="2">PMID: 12216086 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Therapeutic potential of curcumin in human prostate        cancer-I. curcumin induces apoptosis in both androgen-dependent and        androgen-independent prostate cancer cells.</font></strong></em>       <font size="2">Dorai T, Gehani N, Katz A. </font><font size="2">Department of Urology, Columbia University, College of Physicians and        Surgeons, New York, NY 10032, USA.</font><font size="2"><em>Prostate Cancer Prostatic Dis</em>. 2000        Aug;3(2):84-93. </font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12497104" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study of curcumin as alternative nontoxic means of inducing the apoptosis        potential in both androgen-dependent and hormone refractory prostate        cancer cells.</font><font size="2">PMID: 12497104 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><strong><em><font size="2">Antiproliferative effect of curcumin (diferuloylmethane)        against human breast tumor cell lines.</font></em></strong><font size="2">       Mehta K, Pantazis P, McQueen T, Aggarwal BB. </font><font size="2">Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer        Center, Houston 77030, USA.</font><font size="2"><em>Anticancer Drugs.</em> 1997 Jun;8(5):470-81.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9215611" target="_blank">Abstract</a></font></p>
<p><font size="2">Curcumin is a potent antiproliferative agent for breast tumor cells and        may have potential as an anticancer agent. </font><font size="2">PMID: 9215611</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Effect of bioflavonoids quercetin and curcumin on        ischemic renal injury: a new class of renoprotective agents.</strong></em></font>       <font size="2">Shoskes DA. </font><font size="2">Department of Surgery, Harbor-UCLA Medical Center, UCLA School of        Medicine, Torrance, California 90509, USA.</font><font size="2"><em>Transplantation.</em> 1998 Jul 27;66(2):147-52.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9701255" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study of the effects of quercetin and curcumin, two bioflavonoids, on        ischemia-reperfusion in the rat.</font><font size="2">PMID: 9701255</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Effect of dietary curcumin and ascorbyl palmitate on        azoxymethanol-induced colonic epithelial cell proliferation and focal        areas of dysplasia.</strong></em></font><font size="2">Huang MT, Deschner EE,        Newmark HL, Wang ZY, Ferraro TA, Conney AH. </font><font size="2">Department of Chemical Biology and Pharmacognosy, College of Pharmacy,        Rutgers University, Piscataway, NJ 08855-0789. </font><font size="2"><em>Cancer Lett. </em>1992 Jun 15;64(2):117-21.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1611594" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study of curcumin and ascorbyl palmitate as antioxidants and as potent        inhibitors of tumor promotion in mouse skin.</font><font size="2">PMID: 1611594</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Curcumin as an inhibitor of cancer.</strong></em></font>       <font size="2">Nagabhushan M, Bhide SV. </font><font size="2">Carcinogenesis Division, Cancer Research Institute, Bombay, India.</font><font size="2"><em>J Am Coll Nutr.</em> 1992 Apr;11(2):192-8.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1578097" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study of the effect of curcumins on different stages of development of        cancer.</font><font size="2">PMID: 1578097 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Curcumin attenuation of acute adriamycin myocardial        toxicity in rats.</font></strong></em><font size="2">Venkatesan N. </font><font size="2">Department of Biochemistry, Central Leather Research Institute, Madras,        India.</font><font size="2"><em>Br J Pharmacol. </em>1998 Jun;124(3):425-7.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9647462" target="_blank">       Abstract</a></font></p>
<p><font size="2">The protective effect of curcumin on acute adriamycin (ADR) myocardial        toxicity in rats.</font><font size="2">PMID: 9647462</font></td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://fourfoldhealing.com/2007/12/30/turmeric/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Digitalis</title>
		<link>http://fourfoldhealing.com/2007/12/30/digitalis/</link>
		<comments>http://fourfoldhealing.com/2007/12/30/digitalis/#comments</comments>
		<pubDate>Mon, 31 Dec 2007 06:01:19 +0000</pubDate>
		<dc:creator>Sabine</dc:creator>
		
		<category><![CDATA[Dr. Cowan Talks On:]]></category>

		<guid isPermaLink="false">http://fourfoldhealing.com/?p=51</guid>
		<description><![CDATA[Digitalis, otherwise known as foxglove, is one of the        most famous medicinal plants in human history. In the late 1700s it was        identified as a medicine for what was then called dropsy, and which is now      [...]]]></description>
			<content:encoded><![CDATA[<p>Digitalis, otherwise known as foxglove, is one of the        most famous medicinal plants in human history. In the late 1700s it was        identified as a medicine for what was then called dropsy, and which is now        referred to as congestive heart failure. It was a medicine that allegedly        made the heart glad. In the next two centuries, it became one of the most        widely used plants for all manner of heart illnesses. The beautiful        foxglove healed the failing heart; it resolved hearts that were beating        too fast or too irregularly. Its effects were rapid, and in those with        failing or irregular hearts, the effects were almost miraculous.</p>
<p>Digitalis has also been known as a potentially dangerous        plant in that taking too much leaves the patient with nausea, anorexia (no        appetite), visual disturbances (especially seeing blue halos around        lights) and eventually even heart arrythmias and death. Digitalis leaves        contain a wide array of constituents, including the main alkaloids digoxin        and digitoxin. Currently it is thought that the main effect of digitalis        on the heart is from digoxin, which is now prescribed in the        semi-synthetic form of Lanoxin.</p>
<p>Some years ago many physicians noticed that their        patients on digitalis preparations, especially those made from whole-leaf        preparations which contain both digoxin and digitoxin, suffered from much        less cancer, or recurrences of pre-existing cancers, than other patients.        I share with you below some of the studies that confirm these        observations, and some of the biochemical reasons why this effect may        occur. For example, one study found that the recurrence rate of women with        breast cancer on digitalis was less than 5% compared to about 30% of those        not on digitalis. Other studies have confirmed this same result. Since the        cancer therapy effect of digitalis is not thought to be found in the        digoxin, but rather in the whole-leaf extract, that is the form that I        use. </p>
<p><strong><em>Please follow the directions for the use of        digitalis carefully, as this is a plant that needs our utmost respect and        care.</em></strong></p>
<p>Following is information for those who wish to read        further on the uses of digitalis, including selected papers from the        National Library of Medicine and other sources, and several websites that        might be of interest. </p>
<p>FYI, I have had numerous requests from patients who are        undergoing treatment for cancer, particularly Iscador therapy, who would        like to talk with other patients about their experiences. We want to act        as a conduit to put people in touch with one another so they can get more        information and share stories. The focus of this       <a href="http://www.fourfoldhealing.com/cancer-discussion">cancer discussion forum</a> is on        patients and their experiences. It will be wholly the effort of those who        have an interest. I will not be involved in any way except as the initial        facilitator for putting people together through a confidential email        exchange. <a href="http://www.fourfoldhealing.com/cancer-discussion">Click here for more        information</a>&#8230;</p>
<p><em><strong>Please note that this        material is for informational and        educational purposes only and is not intended to replace consultation with        a doctor.</strong></em></p>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px" bgcolor="#d2d3d7"><strong>       Selected Papers                  </strong><font size="2">Click on Abstracts to read more via links.</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>       Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell        apoptosis.</strong></em> </font><font size="2">Lin H, Juang JL, Wang PS. </font><font size="2">Division of Molecular and Genomic Medicine, National Health Research        Institutes, Taipei 115, Taiwan, Republic of China.</font><font size="2"><em>J Biol Chem.</em> 2004 Jul 9;279(28):29302-7. Epub        2004 Apr 30. </font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15123618" target="_blank">Abstract</a></font></p>
<p><font size="2">This study&#8217;s results suggest that Cdk5/p35 and p25 are novel players in        digoxin-triggered prostate cancer cell apoptosis and, therefore, become        potential therapeutic targets. </font></p>
<p><font size="2">PMID: 15123618</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Anti-tumour activity of Digitalis purpurea L. subsp.        heywoodii. </font></strong></em><font size="2">Lopez-Lazaro M, Palma De La Pena N, Pastor N,        Martin-Cordero C, Navarro E, Cortes F, Ayuso MJ, Toro MV. </font><font size="2">Departamento de Farmacologia, Facultad de Farmacia, Universidad de Sevilla,        Spain. </font><font size="2"><em>Planta Med. </em>2003 Aug;69(8):701-4. </font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14531018" target="_blank">Abstract</a></font></p>
<p><font size="2">Four extracts obtained from the leaves of Digitalis purpurea subsp.        heywoodii have been assessed for cytotoxic activity against three human        cancer cell lines. </font></p>
<p><font size="2">PMID: 14531018 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>The dynamics of cell proliferation.</strong></em> </font><font size="2">John F. Moxnes, Johan Haux and Kjell Hausken </font><font size="2">Received 7 Mar 2003; accepted 23 Dec 2003. Available online 27 Feb 2004.</font><font size="2">       <a href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6WN2-4BT8G0X-8&amp;_coverDate=12/31/2004&amp;_alid=158818535&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_qd=1&amp;_cdi=6950&amp;_sort=d&amp;view=c&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=54aa99d2aa59eb1c305b345a4e" target="_blank">Abstract</a></font></p>
<p><font size="2">(from sciencedirect.com)</font></p>
<p><font size="2">The article provides a mathematical description based on the theory of        differential equations, for the proliferation of malignant cells (cancer).</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Digitalis; impinges on more than just the (ion-)        pump.</font></strong></em><font size="2">Haux J </font><font size="2">Department of Oncology, St Olav&#8217;s University Hospital, Trondheim, Norway.</font><font size="2"><em>Medical Hypotheses,</em> Volume 59, Issue 6 , 12 November        2002, Pages 781-782</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12445525" target="_blank">Abstract</a></font></p>
<p><font size="2">Digitalis has complex dose-dependent mechanisms of action involving many        signaling systems and the relevance of this for the anticancer effects are        discussed.</font></p>
<p><font size="2">PMID: 12445525</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Digitoxin medication and cancer; case control and        internal dose-response studies</font></strong></em><font size="2">Haux J,        Klepp O, Spigset O, Tretli S. </font><font size="2">Department of Oncology, University Hospital, N-7006, Trondheim, Norway.</font><font size="2"><em>BMC Cancer</em>. 2001;1(1):11. Epub 2001 Aug 10.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11532201" target="_blank">Abstract</a></font></p>
<p><font size="2">This paper investigates if patients taking digitoxin for cardiac disease        have a different cancer incidence compared to the general population.</font></p>
<p><font size="2">PMID: 11532201</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Digitoxin decreases cell growth and may work as        radiosensitizer in glioblastoma cell lines</strong></em></font>       <font size="2">ABL Marthinsen PhD, T Strickert MSc, KM Jensen MSc, J Haux        MD</font><font size="2"><em>Cancer Detection and Prevention 2000;</em>        24(Supplement 1). </font><font size="2">       <a href="http://www.cancerprev.org/Journal/Issues/24/101/410/3849" target="_blank">Abstract</a> </font><font size="2">Paper presented at the International Symposium on Impact of Biotechnology        on Cancer Diagnostic &amp; Prognostic Indicators; Geneva, Switzerland; October        28 - 31, 2000; in the section on synergistic therapies.</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Digitoxin is a potential anticancer agent for        several types of cancer</font></strong></em><font size="2">J. Haux Institute        of Cancer Research and Molecular Biology, Norwegian University of Science        and Technology, Trondheim, Norway </font><font size="2">Institute of Cancer Research and Molecular Biology, Norwegian University        of Science and Technology, Trondheim.</font><font size="2"><em>Med        Hypotheses.</em> 1999 Dec;53(6):543-8.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10687899" target="_blank">Abstract</a></font></p>
<p><font size="2">This article studies features of the cardiac glycosides which make them        interesting to evaluate further as potential anticancer drugs are        discussed. Some new data concerning inhibition and apoptosis in three        human glioblastoma cell lines by digitoxin are also presented.</font></p>
<p><font size="2">Publication Types: Review, Tutorial</font></p>
<p><font size="2">PMID: 10687899</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Digitoxin, in non-toxic concentrations, inhibits        proliferation and induces cell death in prostate cancer cell lines </font>       </strong></em><font size="2">Haux J, Solheim O, Isaksen T, Angelsen A.</font><font size="2"><em>Z-ONKOL. Zeitschrift für Onkologie</em>. 2000; 32/1        (11-16)</font><font size="2">Abstract: </font><font size="2">In an earlier study we found apoptosis induction in human leukemia cell        lines by digitoxin. The main known pharmacological effect of digitoxin is        Na+/K+ATPase inhibition. In fact, the Na+/K+ATPase has been proposed to be        the actual androgen receptor of the prostate. Hence, it is of interest to        examine the effects of the clinically used cardiac glycosides digoxin and        digitoxin on human prostate cancer cell lines. In the present study we        assessed the cancer prostate cancer cell lines LNCaP, PC-3, TSU-pr1 and        DU-145 for susceptibility to digoxin and digitoxin. Digoxin, in clinically        relevant concentrations, induced minor inhibition of viability, whereas        digitoxin potently inhibited all 4 cell lines. DNA histogram analysis        revealed an accumulation of the digitoxin treated cells in the G2M phase        of the cell cycle as well as DNA fragmentation. Proliferation data, MTT        data and DNA histograms together with phase contrast light microscopy        indicated cell death induced through apoptosis. These results imply a        possible role for cardiac glycosides in the management of prostate cancer.</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Digitoxin, in non toxic concentrations,        induces apoptotic cell death in Jurkat T cells in vitro.</strong></em> </font><font size="2">Haux J, Lam M, Marthinsen ABL, Strickert T, Lundgren S.</font><font size="2"><em>Z-ONKOL. Zeitschrift für Onkologie</em>. 1999; 31/1        (14-20).</font><font size="2">Abstract:</font></p>
<p><font size="2">Reports concerning the anti-cancer effects of digitalis interested us in        performing an in vitro study of digitoxin and digoxin on 5 different        malignant cell lines. Two breast cancer cell lines, MDA-MB-231 (receptor        negative), T47D (receptor positive) and three malignant hematological cell        lines, Jurkat, Daudi and K562, were tested for sensitivity for digitoxin        and digoxin.</font></p>
<p><font size="2">Peripheral blood mononuclear cells (PBMC) and natural killer cells (NK),        both non stimulated and interleukin 2 (IL-2) stimulated, were used as        control cells. Digitoxin has growth inhibitory effects on both breast        cancer cell lines and inhibited proliferation and decreased viability of        two of the three malignant hematological cell lines tested. Digitoxin        exerted these effects in therapeutic concentrations for treating cardiac        congestion. In the hematological cell lines Jurkat and Daudi digitoxin        induced apoptotic cell death. PBMC and NK cells, both non-stimulated and        IL-2 stimulated, were not affected by the same concentrations of digitoxin.        Digoxin also showed inhibiting properties on the malignant cell lines, but        the effects were less pronounced and not dose dependent. Digitoxin may be        a prototype anticancer drug exerting its effect through a mechanism other        than cytotoxicity.</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><strong><em><font size="2">Digitoxin sensitizes malignant breast cancer cells        for radiation in vitro.</font></em></strong><font size="2">Haux J, Marthinsen        ABL, Gulbrandsen M, Alfredsen AS, Johansen H, Strickert T, Lundgren S.</font><font size="2"><em>Z-ONKOL. Zeitschrift für Onkologie.</em> 1999; 31/3        (61-65).</font><font size="2">Abstract: </font><font size="2">The malignant breast cancer cell lines T47D and MDA-MB-231 were examined        for altered radiosensitivity during treatment with the cardiac glycosides        digoxin and digitoxin. The effects were assessed with a clonogenic assay        and DNA histograms. Digitoxin sensitized both cell lines for radiation        when applied at least 3 days before radiation. Digoxin also induced        changes in radiosensitivity, but not to the same extent. Digitoxin seem to        halt T47D and MDA-MB-231 in the G2M phase of the cell cycle and this may        be one explanation for the increased radiosensitivity. </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><strong><em><font size="2">The role of interleukin-2 in regulating the        sensitivity of natural killer cells for Fas-mediated apoptosis.</font></em></strong><font size="2">Haux J, Johnsen AC, Steinkjer B, Egeberg K, Sundan A,        Espevik T </font><font size="2">Institute of Cancer Research and Molecular Biology, Norwegian University        of Science and Technology, Trondheim.</font><font size="2"><em>Cancer        Immunol Immunother</em> 1999 May-Jun;48(2-3):139-46</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10414468" target="_blank">Abstract</a></font></p>
<p><font size="2">Study of the role that Fas/Fas-ligand (FasL) system seems to play a key        role in regulating immunoresponses.</font></p>
<p><font size="2">PMID: 10414468</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Regulation of APO-2 ligand/trail expression in NK        cells-involvement in NK cell-mediated cytotoxicity. </font></strong></em><font size="2">Johnsen AC, Haux J, Steinkjer B, Nonstad U, Egeberg K,        Sundan A, Ashkenazi A, Espevik T. </font><font size="2">Department of Cancer Research and Molecular Biology, Norwegian University        of Science and Technology, Trondheim, Norway.</font><font size="2"><em>Cytokine.</em> 1999 Sep;11(9):664-72. Related        Articles, Links </font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10479402" target="_blank">Abstract</a></font></p>
<p><font size="2">A study that shows that Apo-2L is        expressed and utilized by human Natural Killer (NK) cells.</font></p>
<p><font size="2">PMID: 10479402</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Regulation of Fas and Fas-ligand expression in NK        cells by cytokines and the involvement of Fas-ligand in NK/LAK        cell-mediated cytotoxicity.</font></strong></em><font size="2">Medvedev AE,        Johnsen AC, Haux J, Steinkjer B, Egeberg K, Lynch DH, Sundan A, Espevik T. </font><font size="2">Institute of Cancer Research and Molecular Biology, Norwegian University        of Science and Technology, Trondheim, Norway.</font><font size="2"><em>       Cytokine.</em> 1997 Jun;9(6):394-404.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9199873" target="_blank">Abstract</a></font></p>
<p><font size="2">This study demonstrates cytokine-mediated regulation of Fas and Fas-ligand        (Fas-L) expression in human NK cells and the involvement of the Fas-L        pathway in NK/LAK cytotoxicity.</font></p>
<p><font size="2">PMID: 9199873</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>       Inhibitory effects of digitalis on the proliferation of androgen dependent        and independent prostate cancer cells.</strong></em> </font><font size="2">Yeh JY, Huang WJ, Kan SF, Wang PS. </font><font size="2">Department and Graduate Institute of Physiology, School of Life Science,        National Yang-Ming University, Taipei, Taiwan, Republic of China. </font><font size="2"><em>J Urol.</em> 2001 Nov;166(5):1937-42.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11586264" target="_blank">Abstract</a></font></p>
<p><font size="2">Study evaluating the effects and underlying mechanisms of cardiac        glycosides, including digoxin, digitoxin and ouabain, on the proliferation        of hormone dependent and independent prostate cancer cell lines.</font></p>
<p><font size="2">PMID: 11586264</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">Is        digitalis a therapy for breast carcinoma? </font></strong></em><font size="2">Stenkvist B. </font><font size="2">Institute of Pathology, University of Uppsala, Uppsala, Sweden. </font><font size="2"><em>Oncol Rep</em>. 1999 May-Jun;6(3):493-6. </font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10203580" target="_blank">Abstract</a></font></p>
<p><font size="2">Long-term follow-up (22.3 years) of 175 patients with breast carcinoma, of        which 32 were on digitalis treatment, when they acquired their breast        carcinoma. </font></p>
<p><font size="2">PMID: 10203580</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">       Evidence of a modifying influence of heart glucosides on the development        of breast cancer. </font></strong></em><font size="2">Stenkvist B, Bengtsson E, Eklund G, Eriksson O,        Holmquist J, Nordin B, Westman-Naeser S.</font><font size="2"><em>Anal Quant Cytol</em>. 1980 Mar-Apr;2(1):49-54.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7377665" target="_blank">Abstract</a> </font><font size="2">Patients on digitalis medication at the time of diagnosis of breast cancer        seem to develop tumors that have a lower growth potential than do patients        not on such medication. These tumors are photometrically characterized by        small nuclei with lower DNA-RNA content and less variation in morphometric        characteristics. </font></p>
<p><font size="2">PMID: 7377665</font></td>
</tr>
</table>
<p><font size="2">Several websites provide additional information on the        therapeutic use of digitalis.</font><font size="2">       <a href="http://www.cancerwire.com/" target="_blank">www.cancerwire.com</a></font></p>
<p><font size="2">Johan Haux, MD, PhD, has conducted many studies and projects. His website        keeps up with the latest in digitalis research.</font></p>
<p><font size="2">       <a href="http://www.annieappleseedproject.org/digitoxin.html" target="_blank">www.annieappleseedproject.org/digitoxin.html</a></font></p>
<p><font size="2">The Annie Appleseed Project includes a page on digitoxins.</font></p>
<p><font size="2">       <a href="http://www.second-opinions.co.uk/heart_drugs.html" target="_blank">http://www.second-opinions.co.uk/heart_drugs.html</a></font></p>
<p><font size="2">In his paper <em>Heart Drugs</em>, Barry Groves talks about        heart drugs and digitalis, leading with this quote: “Digitalis is the        right drug being used to treat the wrong disease.” </font></p>
]]></content:encoded>
			<wfw:commentRss>http://fourfoldhealing.com/2007/12/30/digitalis/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Iscador</title>
		<link>http://fourfoldhealing.com/2007/12/30/iscador/</link>
		<comments>http://fourfoldhealing.com/2007/12/30/iscador/#comments</comments>
		<pubDate>Mon, 31 Dec 2007 05:59:55 +0000</pubDate>
		<dc:creator>Sabine</dc:creator>
		
		<category><![CDATA[Dr. Cowan Talks On:]]></category>

		<guid isPermaLink="false">http://fourfoldhealing.com/?p=50</guid>
		<description><![CDATA[I often treat cancer with Iscador, an alternative and        nontoxic therapy made from a lacto-fermented extract of mistletoe (Viscum        album L.) This treatment is one of the most extensively studied        complementary medical therapies, particularly [...]]]></description>
			<content:encoded><![CDATA[<p>I often treat cancer with Iscador, an alternative and        nontoxic therapy made from a lacto-fermented extract of mistletoe (<em>Viscum        album L</em>.) This treatment is one of the most extensively studied        complementary medical therapies, particularly in Europe where it has been        used as an adjunctive therapy for solid tumor cancers. An early 2005 study confirms the safety of              complementary Iscador therapy in patients with high-risk melanoma.        Equally important, the Iscador users had a significantly improved length        and quality of survival and fewer distant metastasis than those who didn&#8217;t        use Iscador. See below to link to the abstract or download a       <a href="http://www.fourfoldhealing.com/pdfs/Melanomastudy_Bock.pdf" target="_blank">Booklet</a> (PDF        format) about the study.</p>
<p>Because I like to provide information to people to help        them better understand their conditions and their options, I have included        below a selection of papers, studies and trials that have been conducted        using mistletoe extract therapy. Click on the link at Abstract to read the        full abstract at the National Center for Biotechnology        Information’s National Library of Medicine website,        <a href="http://www.ncbi.nlm.nih.gov/" target="_blank">www.ncbi.nlm.nih.gov</a>. At the bottom of this        page, I also include several other websites with additional information        and links on Iscador and cancer therapy.</p>
<p>I have had numerous requests from patients who are        undergoing treatment for cancer, particularly Iscador therapy, who would        like to talk with other patients about their experiences. We want to act        as a conduit to put people in touch with one another so they can get more        information and share stories. The focus of this       <a href="http://www.fourfoldhealing.com/cancer-discussion">cancer discussion forum</a> is on        patients and their experiences. It will be wholly the effort of those who        have an interest. I will not be involved in any way except as the initial        facilitator for putting people together through a confidential email        exchange. <a href="http://www.fourfoldhealing.com/cancer-discussion">Click here for more        information</a>&#8230;</p>
<p><em><strong>Please note that this material is intended for informational and        educational purposes only and is not intended to replace consultation with        a doctor.</strong></em></p>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px" bgcolor="#d2d3d7"><strong>       Selected Papers                  </strong><font size="2">Abstracts link to NCBI&#8217;s National Library of Medicine        PubMed site</font></td>
</tr>
</table>
<p align="left">&nbsp;</p>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">[<em><strong>Safety        and efficacy of the long-term adjuvant treatment of primary intermediate-        to high-risk malignant melanoma (UICC/AJCC stage II and III) with a        standardized fermented European mistletoe (Viscum album L.) extract.        Results from a multicenter, comparative, epidemiological cohort study in        Germany and Switzerland.</strong></em>]</font><font size="2">Augustin M, Bock        PR, Hanisch J, Karasmann M, Schneider B </font><font size="2">Department of Dermatology, University Hospital, University of Freiburg,        Freiburg/Brsg (Germany) </font><font size="2"><em>Arzneimittelforschung</em>. 2005;55(1):38-49.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15727163" target="_blank">Abstract</a>          <a href="http://www.fourfoldhealing.com/Melanomastudy_Bock.pdf" target="_blank">Booklet</a>(</font><font size="1">PDF        format</font><font size="2">)</font></p>
<p><font size="2">The objective of the study was to evaluate the safety and therapeutic        efficacy of a long-term mistletoe therapy with Iscador within the scope of        post-operative treatment in patients with mean- to high-risk primary        malignant melanoma by comparison with a untreated parallel control group.        Conclusion: a long-term Iscador treatment in patients with mean- to        high-risk primary malignant melanoma appears to be safe.</font></p>
<p><font size="2">PMID: 15727163</font></td>
</tr>
</table>
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">[<em><strong>Efficacy        and safety of long-term complementary treatment with standardized European        mistletoe extract (Viscum album L.) in addition to the conventional        adjuvant oncologic therapy in patients with primary non-metastasized        mammary carcinoma. Results of a multi-center, comparative, epidemiological        cohort study in Germany and Switzerland</strong></em>] [</font><font size="1">Article        in German</font><font size="2">]</font><font size="2">Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B. </font><font size="2">Institut fur Angewandte Gesundheitsforschung, IFAG Basel AG, Basel,        Schweiz.</font><font size="2"><em>Arzneimittelforschung</em>. 2004;54(8):456-66.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15460213" target="_blank">Abstract</a>          <a href="http://www.fourfoldhealing.com/BreastCancerstudyBock.pdf" target="_blank">Booklet</a>  (</font><font size="1">PDF        format</font><font size="2">)</font></p>
<p><font size="2">A study to evaluate the therapeutic efficacy and safety of long-term        complementary therapy in primary, non-metastatic mammary carcinoma        patients in UICC stage I-III with a standardized European mistletoe        extract given in addition to conventional adjuvant oncologic therapy.</font></p>
<p><font size="2">Publication Types: Clinical Trial, Multicenter        Study, Randomized Controlled Trial</font></p>
<p><font size="2">PMID: 15460213</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em>       <strong>Impact of complementary mistletoe extract treatment on quality of life        in breast, ovarian and non-small cell lung cancer patients. A prospective        randomized controlled clinical trial.</strong></em></font><font size="2">Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS. </font><font size="2">Guang An Men Hospital, Beijing, China.</font></p>
<p><font size="2"><em>       Anticancer Res</em>. 2004 Jan-Feb;24(1):303-9.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15015612" target="_blank">Abstract</a></font></p>
<p><font size="2">This study showed that complementary treatment with sME can beneficially        reduce the side-effects of chemotherapy in cancer patients and thus        improve quality of life. </font></p>
<p><font size="2">Publication Types: Clinical Trial, Multicenter Study,        Randomized Controlled Trial</font></p>
<p><font size="2">PMID: 15015612 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>       Differential effects of Viscum album extract Iscador(R)Qu on cell cycle        progression and apoptosis in cancer cells.</strong></em></font><font size="2">Harmsma M, Gromme M, Ummelen M, Dignef W, Tusenius KJ, Ramaekers FC. </font><font size="2">Department of Molecular Cell Biology, University of Maastricht, 6200 MD        Maastricht, The Netherlands.</font></p>
<p><font size="2">       <em>Int J Oncol</em>. 2004 Dec;25(6):1521-9.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15547686" target="_blank">Abstract</a></font></p>
<p><font size="2">This study tested the hypothesis that Iscador(R)Qu, an aqueous fermented        extract from the European mistletoe grown on oaks, induces tumor        regression by cell cycle inhibition and/or interference with apoptotic        signaling pathways in cancer cells. </font></p>
<p><font size="2">PMID: 15547686 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Critical role of reactive oxygen species and        mitochondrial membrane potential in korean mistletoe lectin-induced        apoptosis in human hepatocarcinoma cells.</strong></em></font><font size="2">Kim WH, Park WB, Gao B, Jung MH. </font><font size="2">Division of Metabolic Disease, Department of Biomedical Science, National        Institutes of Health, #5 Nokbun-dong, Eunpyung-gu, Seoul 122-701, South        Korea.</font></p>
<p><font size="2"><em>Mol        Pharmacol.</em> 2004 Dec;66(6):1383-96. Epub 2004 Aug 31.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15340045" target="_blank">Abstract</a></font></p>
<p><font size="2">Viscum album L. coloratum agglutinin (VCA), isolated from Korean        mistletoe, is a strong inducer of apoptosis in a variety of tumor cells;        however, the underlying molecular mechanisms responsible are not clear.        This study shows that VCA induces apoptotic killing. </font></p>
<p><font size="2">PMID: 15340045 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">       <em><strong>Influence of postoperative complementary treatment with lectin-standardized        mistletoe extract on breast cancer patients. A controlled epidemiological        multicentric retrolective cohort study.</strong></em></font><font size="2">       Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR,        Hanisch J, Beuth J. </font><font size="2">Institut fuer Biometrie, Medizinische Hochschule Hannover,        Konstanty-Gutschow-Str. 8, 30625 Hannover, Germany. </font></p>
<p><font size="2"><em>       Anticancer Res</em>. 2003 Nov-Dec;23(6D):5081-7.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14981970" target="_blank">Abstract</a></font></p>
<p><font size="2">This epidemiological study was performed to evaluate the influence of        postoperative complementary treatment with lectin-standardized mistletoe        extract (sME) on breast cancer patients. </font></p>
<p><font size="2">Publication Types: Clinical Trial, Multicenter Study,        Randomized Controlled Trial</font></p>
<p><font size="2">PMID: 14981970 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">       <em><strong>Mistletoe and gemcitabine in patients with advanced cancer: a model        for the phase I study of botanicals and botanical-drug interactions in        cancer therapy.</strong></em></font><font size="2">       Mansky PJ, Grem J, Wallerstedt DB, Monahan BP, Blackman MR. </font><font size="2">National Center for Complementary and Alternative Medicine, National        Institutes of Health, Bethesda, MD 20892-2669, USA</font></p>
<p><font size="2">       <em>Integr Cancer Ther</em>. 2003 Dec;2(4):345-52.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14713326" target="_blank">Abstract</a></font></p>
<p><font size="2">While the clinical efficacy of mistletoe in cancer is being investigated,        toxicity and potential interactions of mistletoe with standard        chemotherapeutic agents are unknown. </font></p>
<p><font size="2">PMID: 14713326 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Phase II        study of viscum fraxini-2 in patients with advanced hepatocellular        carcinoma.</strong></em></font><font size="2">Mabed M, El-Helw L, Shamaa S. </font><font size="2">Hematology and Medical Oncology Unit, Faculty of Medicine, Mansoura        University, Mansoura, Egypt</font></p>
<p><font size="2"><em>Br J        Cancer.</em> 2004 Jan 12;90(1):65-9.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14710208" target="_blank">Abstract</a></font></p>
<p><font size="2">This study was conducted to evaluate the efficacy and safety of viscum        fraxini-2 in patients with chemotherapy-naive, advanced hepatocellular        carcinoma. </font></p>
<p><font size="2">Publication Types: Clinical Trial; Clinical Trial, Phase        II</font></p>
<p><font size="2">PMID: 14710208</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>The influence of isorel on the advanced colorectal        cancer</strong></em>.</font><font size="2">Cazacu M, Oniu T, Lungoci C, Mihailov A, Cipak A, Klinger R, Weiss T,        Zarkovic N. </font><font size="2">The 4th Surgical Clinic&#8211;University of Medicine and Pharmacy Iuliu        Hatieganu, Romania.</font></p>
<p><font size="2"><em>       Cancer Biother Radiopharm</em>. 2003 Feb;18(1):27-34.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12667306" target="_blank">Abstract</a></font></p>
<p><font size="2">A study of a therapeutical approach of surgery and chemotherapy combined        with biotherapy by Viscum album extract Isorel, aiming to improve the        patients&#8217; resistance to the disease and to render the treatment&#8217;s side        effects more tolerable. </font></p>
<p><font size="2">Publication Types: Clinical Trial, Randomized Controlled        Trial</font></p>
<p><font size="2">PMID: 12667306</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">[<em><strong>Blood and tissue eosinophilia, mistletoe lectin        antibodies and quality of life in a breast cancer patient undergoing        intratumoral and subcutaneous mistletoe therapy</strong></em>] [</font><font size="1">Article        in German</font><font size="2">]</font><font size="2">Kroz M, Schad F, Matthes B, Pickartz H, Girke M. </font><font size="2">Forschungsinstitut Havelhohe am Gemeinschaftskrankenhaus Havelhohe,        Germany.</font></p>
<p><font size="2">       <em>Forsch Komplementarmed Klass Naturheilkd</em>. 2002 Jun;9(3):160-7.</font></p>
<p><font size="2"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12119512" target="_blank">Abstract</a></font></p>
<p><font size="2">Study of Mistletoe therapy (MT) as a method of complementary medicine,        using high-dose intratumoral application.       </font><font size="2">Publication Types: Case Reports</font></p>
<p><font size="2">PMID: 12119512</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">       <em><strong>Mistletoe viscotoxins increase natural killer cell-mediated        cytotoxicity</strong></em>.</font><font size="2">       Tabiasco J, Pont F, Fournie JJ, Vercellone A. </font><font size="2">Institut National de la Sante et de la Recherche Medicale U563 and Service        de spectrometrie de masse de l&#8217; IFR 30, CHU Purpan, BP3028, Toulouse,        France. </font></p>
<p><font size="2">       <em>Eur J Biochem</em>. 2002 May;269(10):2591-600.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12027898" target="_blank">Abstract</a></font></p>
<p><font size="2">Study to show that nontoxic concentrations of Viscum album extracts        increase natural killer (NK) cell-mediated killing of tumor cells but        spare nontarget cells from NK lysis. </font></p>
<p><font size="2">PMID: 12027898 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Induction of        apoptosis of endothelial cells by Viscum album: a role for anti-tumoral        properties of mistletoe lectins.</strong></em></font><font size="2">Van Huyen JP, Bayry J, Delignat S, Gaston AT, Michel O, Bruneval P,        Kazatchkine MD, Nicoletti A, Kaveri SV. </font><font size="2">INSERM U430, Hopital Broussais, Paris, France.</font></p>
<p><font size="2"><em>Mol        Med</em>. 2002 Oct;8(10):600-6.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12477970" target="_blank">Abstract</a></font></p>
<p><font size="2">Study that tests the hypothesis that VA extracts induce endothelial cell        death and apoptosis. </font></p>
<p><font size="2">PMID: 12477970 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">[<em><strong>Frequency of the common cold in healthy subjects        during exposure to a lectin-rich and a lectin-poor mistletoe preparation        in a randomized, double-blind, placebo-controlled study</strong></em>] [</font><font size="1">Article        in German</font><font size="2">]</font><font size="2">Huber R, Klein R, Ludtke R, Werner M. </font><font size="2">Ambulanz fur Naturheilverfahren/Abteilung Innere Medizin II,        Universitatsklinikum Freiburg i.Br.</font></p>
<p><font size="2">       <em>Forsch Komplementarmed Klass Naturheilkd</em>. 2001 Dec;8(6):354-8.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11799303" target="_blank">Abstract</a></font></p>
<p><font size="2">Mistletoe preparations have immunomodulatory properties in vitro and in        vivo. This study investigates whether or not these properties have an        effect on the frequency of the common cold in healthy subjects. </font></p>
<p><font size="2">Publication Types: Clinical Trial, Randomized Controlled        Trial</font></p>
<p><font size="2">PMID: 11799303 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Use of Iscador, an extract of        European mistletoe (Viscum album), in cancer treatment: prospective        nonrandomized and randomized matched-pair studies nested within a cohort        study.</strong></em></font><font size="2">Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R. </font><font size="2">Institute for Preventive Medicine, European Center for Peace and        Development, United Nations, Heidelberg, Germany. </font></p>
<p><font size="2">       <em>Altern Ther Health Med</em>. 2001 May-Jun;7(3):57-66, 68-72, 74-6        passim.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11347286" target="_blank">Abstract</a></font></p>
<p><font size="2">Study to determine whether Iscador treatment prolongs survival time of        patients with carcinomas and to explore synergies between Iscador        treatment and psychosomatic self-regulation. </font></p>
<p><font size="2">Publication Types: Clinical Trial, Multicenter Study,        Randomized Controlled Trial</font></p>
<p><font size="2">PMID: 11347286</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">       Potentiation of tumor necrosis factor-alpha-induced apoptosis by mistletoe        lectin.</font></strong></em><font size="2">Pae HO, Seo WG, Oh GS, Shin MK,        Lee HS, Lee HS, Kim SB, Chung HT. </font><font size="2">Department of Microbiology and Immunology, Wonkwang University School of        Medicine, Iksan, Korea. </font><font size="2"><em>Immunopharmacol Immunotoxicol.</em> 2000        Nov;22(4):697-709.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11105782" target="_blank">Abstract</a></font></p>
<p><font size="2">Mistletoe lectins (MLs) constitute the active principle in extract        preparations from mistletoe, commonly used as immunomodulator in adjuvant        tumor therapy. </font></p>
<p><font size="2">PMID: 11105782 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">[<em><strong>Mistletoe        extracts in the therapy of malignant, hematological and lymphatic        diseases--a monocentric, retrospective analysis over 16 years</strong></em>] [</font><font size="1">Article        in German</font><font size="2">] </font><font size="2">Stumpf C, Rosenberger A, Rieger S, Troger W, Schietzel        M.<em> </em></font><font size="2">Forsch Komplementarmed Klass Naturheilkd. </font><font size="2"><em>Krebsforschung Herdecke e.V.,        Gemeinschaftskrankenhaus Herdecke</em>. 2000 Jun;7(3):139-46. </font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10899748" target="_blank">Abstract</a></font></p>
<p><font size="2">A study to investigate potentials risks of treatment with mistletoe        extracts in patients with malignant haematological and lymphatic diseases.       </font></p>
<p><font size="2">PMID: 10899748</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">       Activation of c-Jun N-terminal kinase 1 (JNK1) in mistletoe lectin        II-induced apoptosis of human myeloleukemic U937 cells.</font></strong></em>       <font size="2">Park R, Kim MS, So HS, Jung BH, Moon SR, Chung SY, Ko CB,        Kim BR, Chung HT. </font><font size="2">Department of Microbiology, Professional Graduate School of Oriental        Medicine, Wonkwang University School of Medicine, 570-749, Iksan Chonbuk,        South Korea. </font><font size="2"><em>Biochem Pharmacol. </em>2000 Dec 1;60(11):1685-91.       </font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11077051" target="_blank">Abstract</a></font></p>
<p><font size="2">Study of extracts of mistletoe (Viscum album var. coloratum) and the        mechanism by which the plant extracts kill tumor cells has remained        elusive. </font></p>
<p><font size="2">PMID: 11077051</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><em><strong><font size="2">       Biological effects of natural and recombinant mistletoe lectin and an        aqueous mistletoe extract on human monocytes and lymphocytes in vitro.</font></strong></em>       <font size="2">Elsasser-Beile U, Voss M, Schuhle R, Wetterauer U. </font><font size="2">Department of Urology, University of Freiburg, Germany.</font><font size="2"><em>Clin Lab Anal</em>. 2000;14(6):255-9. </font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11138605" target="_blank">Abstract</a></font></p>
<p><font size="2">A study to compares the immunological potency of different well-defined        mistletoe lectin preparations on human immune cells. </font></p>
<p><font size="2">PMID: 11138605</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Hypereosinophilia induced by high-dose intratumoral        and peritumoral mistletoe application to a patient with pancreatic        carcinoma.</strong></em> </font><font size="2">Huber R, Barth H, Schmitt-Graff A, Klein R. </font><font size="2">Center for Complementary Medicine, Department of Gastroenterology,        University of Freiburg, Germany.</font><font size="2"><em>J Altern        Complement Med.</em> 2000 Aug;6(4):305-10. </font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10976976" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study of a patient with inoperable adenocarcinoma of the pancreas treated        with intraperitumoral and peritumoral injections of a mistletoe extract.       </font></p>
<p><font size="2">Publication Types: Case Reports</font></p>
<p><font size="2">PMID: 10976976 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Antitumoral effects of an intravesically applied        aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice.</strong></em></font>       <font size="2">Mengs U, Schwarz T, Bulitta M, Weber K. </font><font size="2">Madaus AG, Ostmerheimer Strasse 198, D-51109 Koln, Germany.</font><font size="2"><em>Anticancer Res</em>. 2000 Sep- Oct;20(5B):3565-8.       </font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11131663" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study to investigate the effects of a locally applied aqueous mistletoe        extract on the growth of urinary bladder carcinoma. </font></p>
<p><font size="2">PMID: 11131663 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Tolerability of an extract of European mistletoe        among immunocompromised and healthy individuals. </strong></em></font><font size="2">Gorter RW, van Wely M, Reif M, Stoss M. </font><font size="2">University of California, San Francisco, USA. </font><font size="2"><em>Altern Ther Health Med.</em> 1999 Nov;5(6):37-44,        47-8.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10550904" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study to determine the toxicity profile and biochemical effects of a        Viscum album extract. </font></p>
<p><font size="2">Publication Types: Clinical Trial, Review, Tutorial</font></p>
<p><font size="2">PMID: 10550904 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Insulin-secreting activity of the traditional        antidiabetic plant Viscum album (mistletoe).</strong></em> </font><font size="2">Gray AM, Flatt PR. </font><font size="2">School of Biomedical Sciences, University of Ulster, Coleraine, Northern        Ireland BT52 1SA, UK. </font><font size="2"><em>J Endocrinol. </em>1999 Mar;160(3):409-14. </font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10076186" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study of effects and presence of insulin-releasing natural product(s) in        Viscum album which may contribute to the reported antidiabetic property of        the plant. </font></p>
<p><font size="2">PMID: 10076186</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">[<em><strong>Mistletoe therapy from the pharmacologic perspective</strong></em>]        [</font><font size="1">Article in German</font><font size="2">] </font><font size="2">Hajto T, Hostanska K, Saller R. </font><font size="2">Abteilung Naturheilkunde, Departement Innere Medizin,        Universitatsspital Zurich, Schweiz. </font><font size="2"><em>Forsch Komplementarmed.</em> 1999 Aug;6(4):186-94.</font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10529578" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study of experimental data that suggest that the mistletoe lectins Viscum        album agglutinin (VAA)-I and -II are play an important role in the        efficacy of mistletoe therapy. </font></p>
<p><font size="2">Publication Types: Review, Academic Review</font></p>
<p><font size="2">PMID: 10529578</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2">[<em><strong>Iscador QuS and human recombinant interferon alpha (Intron        A) in cervical intraepithelial neoplasia (CIN)]</strong></em> [</font><font size="1">Article        in Polish</font><font size="2">] </font><font size="2">Jach R, Basta A. </font><font size="2">Katedry i Kliniki Ginekologii i        Onkologii Collegium Medicum Uniwersytetu Jagiellonskiego w Krakowie.       </font><font size="2"><em>Przegl Lek.</em> 1999;56(1):86-8</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10375935" target="_blank">       Abstract</a></font></p>
<p><font size="2">The aim of this work was the evaluation of the Iscador QuS and Intron A        role in the management of HPV associated CIN. </font></p>
<p><font size="2">Publication Types: Clinical Trial, Controlled Clinical        Trial</font></p>
<p><font size="2">PMID: 10375935 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>Direct and rapid induction of migration in human CD4+        T lymphocytes within three-dimensional collagen matrices mediated by        signalling via CD3 and/or CD2.</strong></em> </font><font size="2">Nikolai G, Niggemann B, Werner M, Zanker KS, Friedl P. </font><font size="2">Institute of Immunology, University of Witten/Herdecke, D-58448 Witten,        Germany. </font><font size="2"><em>Immunology. </em>1998 Sep;95(1):62-8. </font></p>
<p><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9767458" target="_blank">       Abstract</a></font></p>
<p><font size="2">Study of specific activation of T cells which require stable cell-cell        interaction; however, little is known how the transition from a previously        motile state into a sessile state following activation is achieved. </font></p>
<p><font size="2">PMID: 9767458</font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>[What prospects of success does Iscador therapy offer        in advanced ovarian cancer?</strong></em>] [</font><font size="1">Article in        German</font><font size="2">] </font><font size="2">Hassauer W, Gutsch J, Burkhardt R. </font><font size="2"><em>Onkologie.</em> 1979 Feb;2(1):28-36.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=392367" target="_blank">       Abstract</a></font></p>
<p><font size="2">A study of the carcinostatic effect of Iscador in the treatment of        carcinoma of the ovary. </font></p>
<p><font size="2">Publication Types: Clinical Trial </font></p>
<p><font size="2">PMID: 392367 </font></td>
</tr>
</table>
<p align="left">
<table border="0" width="600">
<tr>
<td style="border-style: solid; border-width: 1px"><font size="2"><em><strong>[Investigation to improve the survival of patients        with bronchial carcinomas "radically operated" (author's transl)] </strong></em>       [</font><font size="1">Article in German</font><font size="2">] </font><font size="2">Salzer G.</font><font size="2"><em>Z Erkr Atmungsorgane</em>. 1975        Feb;142(2):127-31.</font><font size="2">       <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1226878" target="_blank">       Abstract</a></font></p>
<p><font size="2">Postoperative treatment (using Iscador) of patients with successfully        resected bronchial carcinoma is described. </font></p>
<p><font size="2">PMID: 1226878</font></td>
</tr>
</table>
<p><font size="2">Weleda’s website has useful information on their        product,       <a href="http://usa.weleda.com/medicine/iscar.asp" target="_blank">Iscador</a>,        including information on       <a href="http://articles.weleda.com/List.asp?TextLike=Iscador&amp;Archive=0&amp;ArticlesOrder=PUBARTICLE_PublishedOnDate&amp;ArticlesDir=desc&amp;RecordsPerPage=25" target="_blank">published data and articles</a>.</font></p>
<p><font size="2">The Townsend        Letter for Doctors and Patients (October 2002)</font></p>
<p><font size="2"><a href="http://www.townsendletter.com/Oct_2002/mistletoecancer1002.htm" target="_blank">       Article on Mistletoe Extracts &amp; Cancer Therapy</a></font></p>
]]></content:encoded>
			<wfw:commentRss>http://fourfoldhealing.com/2007/12/30/iscador/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Medicines and Supplements</title>
		<link>http://fourfoldhealing.com/2007/12/30/medicines-and-supplements/</link>
		<comments>http://fourfoldhealing.com/2007/12/30/medicines-and-supplements/#comments</comments>
		<pubDate>Mon, 31 Dec 2007 05:58:16 +0000</pubDate>
		<dc:creator>Sabine</dc:creator>
		
		<category><![CDATA[Medicine &amp; Supplements]]></category>

		<guid isPermaLink="false">http://fourfoldhealing.com/?p=49</guid>
		<description><![CDATA[The following information is        complementary to my Diet and Nutrition information sheet, in which I tried        to make clear which foods I consider to be of the best quality for        maintaining good health and [...]]]></description>
			<content:encoded><![CDATA[<p><font size="2">The following information is        complementary to my <a href="http://www.fourfoldhealing.com/Diet_and_Nutrition.htm">Diet and Nutrition</a> information sheet, in which I tried        to make clear which foods I consider to be of the best quality for        maintaining good health and promoting healing. In this piece, I do the        same on the subjects of medicines and supplements. As with food, achieving        optimal health or recovering from an illness requires bringing as much        thought and insight to bear on this subject as is possible. We cannot        afford to make the mistake of using unbalanced vitamins or inferior        quality medicines in this quest for improved health. Currently, I use        medicines and supplements from five sources. I would like to explain why I        believe that these are the best sources of medicines and supplements        available. But before I do that, I would like to talk about my general        therapeutic strategy.</font></p>
<p class="MsoNormal"><strong><font size="2">My Therapeutic Strategy<br />
</font></strong><font size="2">     Generally, after I see        a patient, listen to his or her story, and do whatever exams and tests are        necessary, I then prescribe a course of treatment. It is important to know        that I am not so much trying to fix what is wrong, but rather to        strengthen patients so that out of their own forces they can begin to        overcome